KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Accumulated Expenses (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Accumulated Expenses data on record, last reported at $1.0 billion in Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 13.53% year-over-year to $1.0 billion; the TTM value through Dec 2025 reached $1.0 billion, up 13.53%, while the annual FY2025 figure was $1.0 billion, 13.53% up from the prior year.
  • Accumulated Expenses reached $1.0 billion in Q4 2025 per JAZZ's latest filing, up from $1.0 billion in the prior quarter.
  • Across five years, Accumulated Expenses topped out at $1.1 billion in Q1 2025 and bottomed at $666.3 million in Q4 2021.
  • Average Accumulated Expenses over 5 years is $874.5 million, with a median of $826.5 million recorded in 2024.
  • Peak YoY movement for Accumulated Expenses: soared 88.9% in 2021, then decreased 1.16% in 2023.
  • A 5-year view of Accumulated Expenses shows it stood at $666.3 million in 2021, then increased by 20.55% to $803.3 million in 2022, then decreased by 1.16% to $793.9 million in 2023, then increased by 14.74% to $910.9 million in 2024, then grew by 13.53% to $1.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Expenses were $1.0 billion in Q4 2025, $1.0 billion in Q3 2025, and $1.1 billion in Q1 2025.